iBio (IBIO) clarifies warrant expirations and advances IBIO-600 Phase 1 trial

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K/A

Rhea-AI Filing Summary

iBio, Inc. filed an amended report to correct and update details about its Series G warrants and related share counts, and to describe progress on its IBIO-600 program. The amendment clarifies that Series G warrants to purchase up to 35,770,000 shares of common stock now expire at 5:00 p.m. New York City time on May 20, 2026, based on a recent clinical milestone announcement.

The company previously issued pre-funded warrants for up to 71,540,000 shares and matching Series G and Series H warrants in an August 2025 financing. As of April 17, 2026, Series G warrants to buy up to 11,065,000 shares remain outstanding, and common shares outstanding total 36,143,561. The filing also notes Australian regulatory and ethics approvals enabling a first-in-human Phase 1 clinical trial of IBIO-600, with first participants expected to be dosed in the second quarter of 2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Series G warrants original size: 35,770,000 warrants Series G warrants outstanding: 11,065,000 warrants Common shares outstanding: 36,143,561 shares +3 more

6 metrics

Series G warrants original size 35,770,000 warrants Aggregate Series G warrants issued in 2025 offering

Series G warrants outstanding 11,065,000 warrants Outstanding as of April 17, 2026

Common shares outstanding 36,143,561 shares Outstanding as of April 17, 2026

Pre-funded warrants 2025 offering 71,540,000 warrants Pre-funded warrants issued August 19, 2025

Additional pre-funded warrants from Series G exercises 13,790,000 warrants Issued upon exercise of Series G warrants after original filing

Series G warrants expiration May 20, 2026, 5:00 p.m. NYC time 30th trading day after public announcement

Key Terms

Series G Warrants, Series H Warrants, pre-funded warrants, Clinical Trial Notification, +2 more

6 terms

Series G Warrants financial

"The terms of the Series G Warrants provide that such warrants expire at 5:00 p.m..."

A Series G warrant is a specific batch of warrants — financial instruments that give the holder the right, but not the obligation, to buy a company’s stock at a set price before a deadline. Think of it like a ticket that lets you lock in today’s price for a future purchase; investors care because exercise can dilute existing shares or provide a way to profit if the stock rises above the ticket price, affecting a company’s value and shareholder returns.

Series H Warrants financial

"Series H warrants (the “Series H Warrants”) to purchase an aggregate of up to 35,770,000 shares..."

Series H warrants are tradable securities that give the holder the right, but not the obligation, to buy a company’s shares at a fixed price before a set expiration; the “Series H” label simply identifies a specific batch of warrants with its own terms. They matter to investors because exercising them increases the number of shares outstanding and can reduce each existing shareholder’s ownership, while also offering a way for warrant holders to lock in a future purchase price—similar to holding a coupon that lets you buy stock later at a preset rate.

pre-funded warrants financial

"the Company issued and sold pre-funded warrants (the “2025 Pre-Funded Warrants”) to purchase an aggregate of up to 71,540,000 shares..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Clinical Trial Notification regulatory

"it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration..."

A clinical trial notification is an official message sent to health regulators or ethics boards to inform them that a company plans to start, change, or stop a medical study involving human volunteers. Investors care because such notifications signal where a drug or medical device stands in the development process, similar to a builder telling city inspectors that construction will begin—helping assess timing, regulatory risk, and potential future value.

Human Research Ethics Committee regulatory

"and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial..."

A human research ethics committee is an independent group that reviews and approves medical or social studies involving people to make sure participants are treated safely, understand the risks, and give proper consent. Think of it as a safety and fairness check before a study can run. For investors, these committees matter because their approval is often required for clinical trials and product testing, and delays or rejection can affect development timelines, regulatory risk and potential returns.

Investigational New Drug application regulatory

"that an Investigational New Drug application filed with the U.S. Food and Drug Administration..."

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

Understanding 8-K Material Events →

04/17/2026 - 05:13 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 8, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)


001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

iBio, Inc. (the “Company”) is filing this Amendment No. 1 on Form 8-K/A (the “Amendment No. 1”) to amend Item 8.01 of the Current Report on Form 8-K it filed with the Securities and Exchange Commission on April 8, 2026 (the “Original Form 8-K”) to correct a typographical error contained therein regarding the date that the Series G warrants (the “Series G Warrants”) to purchase up to 35,770,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) will expire. As amended, this Amendment No. 1 correctly states that the Series G Warrants will expire at 5:00 p.m. (New York City time) on May 20, 2026. This Amendment No. 1 also updates the number of outstanding Series G Warrants and adds disclosure regarding the number of outstanding shares of the Company’s Common Stock and the issuance of pre-funded warrants upon the exercise of Series G Warrants.

Item 8.01. Other Events.

On April 8, 2026, the Company issued a press release announcing (the “Public Announcement”) that it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia to initiate its Phase 1 clinical trial of IBIO-600 in Australia. First participants are expected to be dosed in the second quarter of 2026.

As previously disclosed, on August 19, 2025, the Company issued and sold pre-funded warrants (the “2025 Pre-Funded Warrants”) to purchase an aggregate of up to 71,540,000 shares of the Company’s Common Stock, and accompanying Series G Warrants to purchase (i) an aggregate of up to 35,770,000 shares of Common Stock (or, for those investors who so chose, pre-funded warrants to purchase up to 35,770,000 shares of Common Stock in lieu thereof) and (ii) Series H warrants (the “Series H Warrants”) to purchase an aggregate of up to 35,770,000 shares of Common Stock (or, for those investors who so chose, pre-funded warrants to purchase up to 35,770,000 shares of Common Stock in lieu thereof) (the “2025 Offering”).

The terms of the Series G Warrants provide that such warrants expire at 5:00 p.m. (New York City time) on the date that is the earlier of (i) 30 trading days following the Company’s Public Announcement, via a press release on a nationally recognized news wire or the filing of a Current Report on Form 8-K with the Securities and Exchange Commission, that an Investigational New Drug application filed with the U.S. Food and Drug Administration, a Clinical Trial Notification filed with the applicable foreign governmental body in Australia, a Clinical Trial Application filed with the European Medicines Agency or an equivalent submission filed with a foreign governmental body to initiate a clinical trial in any other foreign jurisdiction, has been accepted or has otherwise gone into effect, as applicable; and (ii) five years from the date of issuance. As a result of the Public Announcement, the Series G Warrants will be exercisable at any time prior to 5:00 p.m. (New York City time) on May 20, 2026, the 30th trading day following the Public Announcement. When issued upon exercise of the Series G Warrants, the Series H Warrants will expire on the four-year anniversary of the closing date of the 2025 Offering.

As of April 17, 2026, there are outstanding Series G Warrants to purchase (i) an aggregate of up to 11,065,000 shares of Common Stock, based upon all exercises of Series G Warrants through such date (irrespective of whether the shares of Common Stock issuable upon exercise have been issued by the Company’s transfer agent after the Company’s receipt of an exercise notice and funds). If all of the currently outstanding Series G Warrants were exercised into shares of Common Stock prior to their expiration date, an additional 11,065,000 shares of Common Stock will be issued, in addition to Series H Warrants to purchase an aggregate of up to 11,065,000 shares of Common Stock (or pre-funded warrants in lieu thereof).

As of April 17, 2026, there are 36,143,561 shares of Common Stock outstanding. Subsequent to the Original Form 8-K, the Company also issued pre-funded warrants to purchase up to 13,790,000 shares of Common Stock upon the exercise of Series G Warrants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 17, 2026	IBIO, INC.

	By:	/s/ Marc A. Banjak
		Name:	Marc A. Banjak
		Title:	Chief Legal Officer

Source: View Original Filing on SEC EDGAR

FAQ

What does iBio (IBIO) change in this amended 8-K/A filing?

The amended filing corrects the expiration date and outstanding amounts of iBio’s Series G warrants and updates share data. It also adds disclosure about pre-funded warrants issued upon warrant exercise and reiterates regulatory approvals supporting the IBIO-600 Phase 1 clinical trial in Australia.

When do iBio’s Series G warrants now expire according to the amendment?

The amendment clarifies that Series G warrants expire at 5:00 p.m. New York City time on May 20, 2026. This date reflects 30 trading days after a public announcement that IBIO-600 received approvals enabling a first-in-human clinical trial in Australia.

How many Series G warrants and common shares does iBio (IBIO) report as outstanding?

As of April 17, 2026, iBio reports outstanding Series G warrants to purchase up to 11,065,000 shares of common stock. The company also discloses 36,143,561 shares of common stock outstanding on the same date, providing context for potential future issuances.

What prior financing is referenced in iBio’s 8-K/A amendment?

The filing references an August 19, 2025 financing where iBio issued pre-funded warrants for up to 71,540,000 shares and accompanying Series G and Series H warrants. These securities formed part of the 2025 offering structure that underlies the current warrant and share disclosures.

What clinical milestone for IBIO-600 is highlighted in the iBio (IBIO) amendment?

The company notes it received a Clinical Trial Notification acknowledgment from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee. These approvals enable initiation of a first-in-human Phase 1 trial of IBIO-600, with first dosing expected in second-quarter 2026.

How are Series H warrants affected by the exercise of Series G warrants at iBio?

When Series G warrants are exercised, iBio issues corresponding Series H warrants or pre-funded warrants. The filing states that Series H warrants issued upon exercise will expire on the four-year anniversary of the closing date of the 2025 offering, defining their long-term duration.

Filing Exhibits & Attachments

4 documents